Target intelligence / Profile preview

Killer cell lectin-like receptor subfamily C member 2 (KLRC2 (NKG2C))

Target
KLRC2 (NKG2C)
Molecular classification
Receptor, C-type lectin-like receptor, Type II integral membrane protein
01

Overview

Killer cell lectin-like receptor subfamily C member 2 (KLRC2), also known as NKG2C, is a type II integral membrane protein and member of the C-type lectin-like family of natural killer (NK) cell receptors[1][3][4]. Expressed primarily on NK cells, NKG2C forms heterodimers with CD94 to create the CD94/NKG2C activating receptor complex, which recognizes the non-classical MHC class I molecule HLA-E on the surface of potential target cells. Upon binding to HLA-E, NKG2C transmits intracellular activation signals via the DAP12 adapter protein, resulting in NK cell activation and cytotoxic responses[1][2][3]. NKG2C+ NK cells are notably expanded following human cytomegalovirus (CMV) infection, where they acquire memory-like properties and enhanced effector functions[2][3][4]. Genetic deletion or polymorphism of KLRC2 is relatively common in the population and is associated with variable susceptibility to viral infections and immune modulation[4]. KLRC2 is a key regulator of immune surveillance and adaptive features within NK cells, with roles in infection, cancer immunology, and possibly in maternal-fetal tolerance[1][3][4].

Other names
NKG2CNKG2-C type II integral membrane proteinCD159cNKG2-CNK cell receptor CNKG2-C-activating NK receptornatural killer cell receptor G2-CCD159 antigen-like family member C
02

Mechanism of action

- Cell activation through recognition of HLA-E on target cells - Intracellular signal transduction by DAP12 adapter recruitment (activating NK cell cytotoxicity)

03

Biological functions

Immune responseSignal transductionAdaptive natural killer (NK) cell activation
04

Disease associations

Infection (notably human cytomegalovirus (HCMV))Cancer (implicated in tumor cell recognition)Immune deficiency (e.g., NK cell deficiency)Other (maternal-fetal tolerance in pregnancy)
05

Safety considerations

Limited specificity may lead to off-target effects or general NK activation if modulated therapeuticallyPotential risk of immune dysregulation when KLRC2 is therapeutically manipulated
06

Biomarkers

Expansion of NKG2C+ NK cells as a biomarker for cytomegalovirus (CMV) infection/adaptationPresence/absence of KLRC2 gene as a stratification marker in immunological diseases

Beyond the preview

Go deeper on Killer cell lectin-like receptor subfamily C member 2 (KLRC2 (NKG2C)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Killer cell lectin-like receptor subfamily C member 2 (KLRC2 (NKG2C)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call